PriceTargets.com logo

Fusion Pharmaceuticals - FUSN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.25
  • Forecasted Upside: -5.29%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 13 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$21.38 As of 04/25/2024 11:38 AM ET
▼ -0.02 (-0.09%)

This chart shows the closing price for FUSN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FUSN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FUSN

Analyst Price Target is $20.25
▼ -5.29% Downside Potential
This price target is based on 14 analysts offering 12 month price targets for Fusion Pharmaceuticals in the last 3 months. The average price target is $20.25, with a high forecast of $24.00 and a low forecast of $15.00. The average price target represents a -5.29% upside from the last price of $21.38.

This chart shows the closing price for FUSN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 14 investment analysts is to hold stock in Fusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 13 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2024TD CowenReiterated RatingBuy ➝ HoldLow
3/20/2024Bloom BurtonDowngradeBuy ➝ HoldLow
3/20/2024B. RileyDowngradeBuy ➝ Neutral$13.00 ➝ $23.00Low
3/20/2024JonestradingReiterated RatingBuy ➝ HoldLow
3/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$16.00 ➝ $21.00Low
3/19/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
3/19/2024Truist FinancialReiterated RatingBuy ➝ Hold$11.00 ➝ $21.00N/A
3/19/2024Jefferies Financial GroupReiterated RatingBuy ➝ Hold$10.00 ➝ $21.00N/A
3/19/2024Raymond JamesReiterated RatingStrong-Buy ➝ Market PerformN/A
3/19/2024Brookline Capital ManagementDowngradeBuy ➝ HoldN/A
3/19/2024William BlairDowngradeOutperform ➝ Market PerformN/A
3/19/2024WedbushDowngradeOutperform ➝ Neutral$24.00N/A
3/19/2024SVB LeerinkReiterated RatingOutperform ➝ Market Perform$17.00 ➝ $21.00N/A
3/4/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$12.00 ➝ $16.00Low
1/26/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00Low
1/5/2024Bloom BurtonReiterated RatingBuyLow
1/5/2024William BlairReiterated RatingOutperformLow
1/5/2024OppenheimerBoost TargetOutperform ➝ Outperform$13.00 ➝ $15.00Low
1/5/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$15.00 ➝ $16.00Low
1/2/2024WedbushReiterated RatingOutperform$13.00Low
12/27/2023OppenheimerReiterated RatingOutperform ➝ Outperform$13.00Low
12/27/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$12.00 ➝ $15.00Low
12/20/2023Royal Bank of CanadaInitiated CoverageOutperform$12.00Low
11/7/2023WedbushReiterated RatingOutperform$13.00Low
10/3/2023B. RileyReiterated RatingBuy ➝ Buy$13.00Low
9/28/2023OppenheimerInitiated CoverageOutperform$13.00Low
8/28/2023Raymond JamesLower TargetOutperform ➝ Outperform$13.00 ➝ $12.00Low
6/23/2023Raymond JamesInitiated CoverageOutperform$13.00Low
3/30/2023B. RileyReiterated RatingBuy$10.00Low
2/13/2023Brookline Capital ManagementReiterated RatingBuyLow
1/27/2023Morgan StanleyLower TargetOverweight$19.00 ➝ $10.00Low
12/1/2022B. RileyReiterated RatingBuy$10.00N/A
11/30/2022SVB LeerinkInitiated CoverageOutperform$6.00Low
9/15/2022Truist FinancialInitiated CoverageBuyLow
9/6/2022JonestradingInitiated CoverageBuyLow
7/6/2022William BlairInitiated CoverageOutperform ➝ OutperformN/A
5/10/2022WedbushLower TargetOutperform$20.00 ➝ $19.00High
2/2/2022Brookline Capital ManagementReiterated RatingBuyMedium
11/25/2021B. RileyReiterated RatingBuy$17.00Low
8/26/2021B. RileyInitiated CoverageBuy$17.00Medium
8/18/2021Morgan StanleyLower TargetOverweight$20.00 ➝ $19.00High
8/10/2021WedbushReiterated RatingOutperformMedium
5/18/2021Morgan StanleyLower TargetOverweight$21.00 ➝ $20.00Low
4/6/2021Morgan StanleyLower TargetOverweight$23.00 ➝ $21.00Low
12/17/2020Bloom BurtonReiterated RatingBuyMedium
7/21/2020Morgan StanleyInitiated CoverageOverweight$23.00High
7/21/2020Jefferies Financial GroupInitiated CoverageBuy$25.00High
7/21/2020WedbushInitiated CoverageOutperform$25.00High
7/21/2020CowenInitiated CoverageOutperformHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 4 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 12 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
3/26/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 4 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fusion Pharmaceuticals logo
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Read More

Today's Range

Now: $21.38
Low: $21.35
High: $21.41

50 Day Range

MA: $16.67
Low: $9.34
High: $21.43

52 Week Range

Now: $21.38
Low: $2.31
High: $21.55

Volume

58,506 shs

Average Volume

1,967,015 shs

Market Capitalization

$1.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fusion Pharmaceuticals?

The following equities research analysts have issued stock ratings on Fusion Pharmaceuticals in the last twelve months: B. Riley, Bloom Burton, Brookline Capital Management, Jefferies Financial Group Inc., Jonestrading, Leerink Partnrs, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, SVB Leerink LLC, TD Cowen, Truist Financial Co., Wedbush, and William Blair.
View the latest analyst ratings for FUSN.

What is the current price target for Fusion Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Fusion Pharmaceuticals in the last year. Their average twelve-month price target is $20.25, suggesting a possible downside of 5.4%. Wedbush has the highest price target set, predicting FUSN will reach $24.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $15.00 for Fusion Pharmaceuticals in the next year.
View the latest price targets for FUSN.

What is the current consensus analyst rating for Fusion Pharmaceuticals?

Fusion Pharmaceuticals currently has 13 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FUSN, but not buy more shares or sell existing shares.
View the latest ratings for FUSN.

What other companies compete with Fusion Pharmaceuticals?

Other companies that are similar to Fusion Pharmaceuticals include Twist Bioscience, Recursion Pharmaceuticals, Sana Biotechnology, Ginkgo Bioworks and Beam Therapeutics. Learn More about companies similar to Fusion Pharmaceuticals.

How do I contact Fusion Pharmaceuticals' investor relations team?

Fusion Pharmaceuticals' physical mailing address is 270 LONGWOOD ROAD SOUTH, HAMILTON A6, L8P 0A6. The company's listed phone number is 289-799-0891 and its investor relations email address is [email protected]. The official website for Fusion Pharmaceuticals is fusionpharma.com. Learn More about contacing Fusion Pharmaceuticals investor relations.